ReviewNanomedicine (London, England)2025
Emerging nanocarriers as advanced delivery tools for the treatment of leukemia.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Two Worlds, One Battle: How Bacteria and Malignancies Converge on Drug Resistance.International journal of molecular sciences · 2026Review
- An overview of advanced nanocarrier systems for Ibrutinib delivery: overcoming pharmacokinetic barriers and enabling targeted cancer therapy.International journal of pharmaceutics: X · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most common type of blood cancer, leukemia, presents global therapeutic challenges like heterogeneity regarding age, sex, race, and a multiple pool of oncogenes and their complex network. In the last few years, nanotechnology has become the potential solution in leukemic resistance, chemotherapeutic failure, and disease-remission risk. Interestingly, the nanocarriers alone sometimes cannot overcome leukemia's obstacles, which demands a more advanced flagship in the nanocarrier segment like modification of the nanocarrier system, external stimuli for synergistic antileukemic effect, etc. This review has highlighted the need for emerging nanocarriers like exosome-like vesicles, nanodiamonds, nanoflower, etc. and biomimetic nanocarriers that reach the bone marrow niche. Notably, the role of nanoparticle-based vaccines in a disease-remission-free life and novel technology for nanocarrier delivery (microfluidics and plasmonic nanobubbles) have been discussed. This review also focuses on the clinical transition barriers of nanocarriers from the research laboratory. The continual research on novel nanocarriers and integration of new technologies to deliver the nanocarriers in the right way is paving the path for enhanced selectivity and efficacy in leukemia. The promising results in precise drug delivery and leukemic cell destruction are showing its great clinical prospects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.